Feb 23, 2017 at 21:27 | Source: Moneycontrol.com
Data reliability or data integrity are often linked to allegations of data falsification or manipulation, which are cited as main reasons by US FDA for pulling up Indian companies as part of its regulatory scrutiny.
Feb 23, 2017 at 17:54 | Source: Moneycontrol.com
Axis Direct recommended hold rating on Glaxosmithkline Consumer with a target price of Rs 5300 in its research report dated February 21, 2017.
Feb 23, 2017 at 16:26 | Source: CNBC-TV18
Mitessh Thakkar of miteshthacker.com suggests buying Cadila Healthcare with a minimum target of Rs 460.
Feb 23, 2017 at 14:41 | Source: CNBC-TV18
Ashwani Gujral of ashwanigujral.com suggests buying DCB Bank, Cadila Healthcare, IndusInd Bank and Grasim Industries.
Feb 23, 2017 at 14:40 | Source: CNBC-TV18
Mitessh Thakkar of miteshthacker.com recommends buying Wipro and Cadila Healthcare.
Feb 23, 2017 at 13:39 | Source: Moneycontrol.com
Easing regulatory concerns and actions by the US Food and Drug Administration (FDA) will help the sector and improve investor sentiment, Deutsche Bank said in a report.
Feb 22, 2017 at 09:56 | Source: Moneycontrol.com
M&M Finance stock has formed an Inverse Head & Shoulder pattern at the bottom, which is a reversal formation. It is on the verge of break-out and rising with good amount of volumes. We recommend a buy on Exide, add more on dips with a final stop loss at Rs.200 and price target of 240
Feb 22, 2017 at 08:58 | Source: PTI
The India born CEO also participated in a round table at NITI Aayog on tapping into cloud computing for good governance in the country.
Feb 22, 2017 at 08:00 | Source: CNBC-TV18
Dr Reddy's Labs | ITC | Infosys | TCS | Tata Motors | Bharat Electronics | Power Grid | Axis Bank | ONGC | HPCL | BPCL | Castrol India | Castex Technologies | Metalyst Forgings | Disa | ITD Cementation and Elantas Beck are stocks, which are in the news today.
Feb 21, 2017 at 16:58 | Source: PTI
Pragmatic compulsory licensing policy is needed to enable India to look after health of its people as it cannot afford monopoly in healthcare with the challenges it faces, Cipla's Y K Hamied said.